Photo taken from ESMO/X
Jul 5, 2024, 02:27
ESMO – Ipilimumab and nivolumab in unresected advanced Hepatocellular Carcinoma
ESMO shared on X:
“Benefits reported for the combination of ipilimumab and nivolumab further expand alternative therapeutic options for patients with unresected advanced Hepatocellular Carcinoma.
Read the opinion piece by Angela Lamarca on ESMO Daily Reporter.”
Read further.
Source: ESMO/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Oct 5, 2024, 23:20
Oct 5, 2024, 23:14
Oct 5, 2024, 19:23
Oct 5, 2024, 19:05
Oct 5, 2024, 18:54